We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Contravir Pharmaceuticals (MM) | NASDAQ:CTRV | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.58 | 3.50 | 3.67 | 0 | 01:00:00 |
ContraVir Pharmaceuticals, Inc.
399 Thornall Street
Edison, NJ 08837
|
June 13, 2019 |
VIA EDGAR
United States Securities
and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Dorrie Yale
Re: ContraVir Pharmaceuticals, Inc.
Form S-1, as amended
File No. 333-231604
Dear Ms. Yale:
ContraVir Pharmaceuticals, Inc. (the Company) hereby respectfully withdraws its request, dated June 12, 2019, that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:30 p.m., Eastern Time, on Thursday, June 13, 2019. The Company intends to submit a revised acceleration request at a later date.
Please contact Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 if there are any questions with respect to this request.
|
Thank you, |
|
|
|
|
|
CONTRAVIR PHARMACEUTICALS, INC. |
|
|
|
|
|
|
|
|
By: |
/s/ Robert Foster |
|
Name: |
Robert Foster |
|
Title: |
Chief Executive Officer |
1 Year Contravir Pharmaceuticals Inc Chart |
1 Month Contravir Pharmaceuticals Inc Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions